Gilead Sciences (NASDAQ:GILD) has been given a $80.00 price objective by Credit Suisse Group in a research note issued on Wednesday. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target indicates a potential upside of 7.15% from the company’s current price.
A number of other analysts have also recently commented on the stock. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a research report on Friday, October 13th. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Thursday, October 19th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. BMO Capital Markets lowered their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Finally, Mizuho upped their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $85.03.
Shares of Gilead Sciences (NASDAQ GILD) traded up $0.56 during trading on Wednesday, hitting $74.66. 6,639,687 shares of the company’s stock traded hands, compared to its average volume of 7,420,000. The company has a market cap of $97,500.00, a PE ratio of 8.49, a price-to-earnings-growth ratio of -1.52 and a beta of 1.13. Gilead Sciences has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter in the prior year, the company earned $2.75 EPS. The firm’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the transaction, the insider now directly owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $74.64, for a total transaction of $1,119,600.00. Following the transaction, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The disclosure for this sale can be found here. In the last quarter, insiders have sold 396,666 shares of company stock valued at $29,283,517. Corporate insiders own 1.30% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Proficio Capital Partners bought a new position in Gilead Sciences in the 4th quarter valued at about $26,000. Van Hulzen Asset Management LLC raised its holdings in Gilead Sciences by 9.1% in the 2nd quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 100 shares during the period. Hall Laurie J Trustee raised its holdings in Gilead Sciences by 20.0% in the 1st quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 250 shares during the period. Penserra Capital Management LLC raised its holdings in Gilead Sciences by 148.3% in the 3rd quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 774 shares during the period. Finally, Gemmer Asset Management LLC raised its holdings in Gilead Sciences by 15.5% in the 3rd quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 175 shares during the period. Institutional investors own 75.94% of the company’s stock.
WARNING: “Credit Suisse Group Reiterates “$80.00” Price Target for Gilead Sciences (GILD)” was published by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/01/03/credit-suisse-group-reiterates-80-00-price-target-for-gilead-sciences-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.